ClinicalTrials.gg
RecruitingNCT07154290Updated Oct 22, 2026

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of Ubamatamab and Marlotamig in Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer and Metastatic Non Small Cell Lung Cancer, sponsored by Regeneron Pharmaceuticals. Recruiting at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 22, 20262 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals — 2 open to participants now, 11 under way, 2 of them phase 3. Carcinoma, Non-Small-Cell Lung · Regeneron Pharmaceuticals.

Planned enrollment
4th of 18
300 · median 86
Started
2026
with 1 other
Phase 2
7 of 21
1 open now
Primary completion
2030-06
later than 9 of 10 live
Registered
20th of 21
by date

Among the 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals, this one is the 4th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2026, is one of 7 in phase 2, reaches primary completion later than 9 of the 10 other live ones, and was the 20th registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals, or all of them as a file.
02

Study summary

This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with immune-related side effects from ubamatamab.

The study is looking at:

  • How well ubamatamab and marlotamig work(s)
  • The side effects that ubamatamab and marlotamig might cause
  • How much ubamatamab and marlotamig is in the blood at different times
  • If the body makes antibodies to ubamatamab and/or marlotamig, this may cause the ubamatamab to not work as well
03

Conditions studied

  • Non Small Cell Lung Cancer
  • Advanced Non Small Cell Lung Cancer
  • Metastatic Non Small Cell Lung Cancer
  • Carcinoma Non Small Cell Lung

Keywords

  • Mucin-16 (MUC16)
  • Ubamatamab
  • Epidermal Growth Factor Receptor (EGFR)
  • REGN7075
  • Stage IIIB, IIIC or IV
  • Marlotamig
  • NSCLC
  • Advanced NSCLC
  • Metastatic NSCLC
  • Lung Cancer
  • Advanced Lung Cancer
  • Metastatic Lung Cancer
  • Stage IV NSCLC
  • Recurrent NSCLC
  • Unresectable NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Has or cytologically confirmed diagnosis of advanced (stage IIIB not amenable to definitive chemoradiotherapy or stage IIIC) or (stage IV) NSCLC
  2. Has received appropriate standard of care treatment for advanced or metastatic NSCLC, as described in the protocol
  3. If platinum doublet chemotherapy was not administered as first line therapy, it is required in a later line of therapy prior to enrollment unless there is a documented reason why it is not appropriate
  4. Has tumor tissue (archival or fresh) available for testing MUC16 expression by immunohistochemistry inclusion (IHC), as described in the protocol
  5. Has at least 1 radiographically by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) per v1.1 criteria. Target lesions may be located in a previously irradiated field if there is documented (radiographic) disease progression in that site
  6. Has an (ECOG) performance status of 0 or 1

Key Exclusion Criteria:

  1. Has progression of disease fewer than 84 days from starting initial anti-Programmed Cell Death (PD)-(L) 1 therapy
  2. Experienced toxicity related to prior treatment that has not resolved to grade 1 prior to initiation of study intervention (except alopecia, hearing loss, grade 2 neuropathy, or endocrinopathy managed with hormone replacement therapy)
  3. Has untreated or active primary brain tumor, Central Nervous System (CNS) metastases, , or spinal cord compression, as described in the protocol
  4. Current participation OR past participation in another study in which an investigational intervention (eg, drug, vaccine, invasive device) was administered within 4 weeks before planned first dose of study intervention in this clinical study
  5. Has received prior monoclonal antibody against PD-(L)1 within 21 days of the first dose of study intervention
  6. Has had other prior anti-cancer immunotherapy within 21 days prior to study intervention, as described in the protocol
  7. Has received prior cytotoxic chemotherapy within 21 days of the first dose of study intervention
  8. Has received an anti-EGFR antibody therapy within the following drug-specific window prior to first dose of study intervention (approximately 5 half-lives), as described in the protocol

NOTE: Other protocol defined inclusion / exclusion criteria apply

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Arm 1A

    Drug: Ubamatamab · Drug: Sarilumab

  • Experimental
    Arm 1B

    Drug: Ubamatamab · Drug: Marlotamig · Drug: Sarilumab

  • Experimental
    Arm 1C

    Drug: Ubamatamab · Drug: Marlotamig · Drug: Sarilumab

  • Experimental
    Arm 2A

    Drug: Ubamatamab · Drug: Sarilumab

  • Experimental
    Arm 2B

    Drug: Ubamatamab · Drug: Marlotamig · Drug: Sarilumab

  • Experimental
    Arm 2C

    Drug: Ubamatamab · Drug: Marlotamig · Drug: Sarilumab

Interventions

  • Administered per the protocol

    Also known as: REGN4018

  • DrugMarlotamig

    Administered per the protocol

    Also known as: REGN7075

  • Administered per the protocol

    Also known as: REGN88SAR153191, KEVZARA®

06

What researchers measure

Primary outcomes

  1. Objective response as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    Time frame: Up to 5 years

Secondary outcomes

  1. Occurrence of Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to 5 years

  2. Severity of TEAEs

    Time frame: Up to 5 years

  3. Occurrence of Treatment-Related Adverse Events (TRAEs)

    Time frame: Up to 5 years

  4. Severity of TRAEs

    Time frame: Up to 5 years

  5. Occurrence of Adverse Events of Special Interest (AESIs)

    Time frame: Up to 5 years

  6. Severity of AESIs

    Time frame: Up to 5 years

  7. Occurrence of Serious Adverse Events (SAEs)

    Time frame: Up to 5 years

  8. Severity of SAEs

    Time frame: Up to 5 years

  9. Occurrence of grade ≥2 Cytokine Release Syndrome (CRS) by Lee Criteria

    Time frame: Up to 5 years

  10. Duration of Response (DOR) as assessed by the investigator per RECIST v1.1

    Time frame: Up to 5 years

  11. Progression-Free Survival (PFS) as assessed by the investigator per RECIST v1.1

    Time frame: Up to 5 years

  12. Best Overall Response (BOR) of confirmed Complete Response (CR) per RECIST v1.1

    Time frame: Up to 5 years

  13. Disease Control Rate (DCR) as assessed by the investigator per RECIST v1.1

    Time frame: Up to 5 years

  14. Incidence of Anti-Drug Antibodies (ADA) to ubamatamab

    Time frame: Up to 5 years

  15. Incidence of ADA to marlotamig

    Time frame: Up to 5 years

  16. Magnitude of ADA to ubamatamab

    Time frame: Up to 5 years

  17. Magnitude of ADA to marolotamig

    Time frame: Up to 5 years

  18. Concentrations of ubamatamab in serum

    Time frame: Up to 5 years

  19. Concentrations of marlotamig in serum

    Time frame: Up to 5 years

07

Study locations

18 of 18 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jun 2030, 50 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 50 months is above that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2025
First posted
Sep 4, 2025
StartActual
Mar 18, 2026
Primary completionEst.
Jun 10, 2030
CompletionEst.
Jun 10, 2030
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 United States)
  • ChristianaCare Health System · Newark, United States
  • Oregon Health and Science University · Portland, United States
across 2 updates, Sep 25, 2026 – Oct 22, 2026
Show all 2 updates
  1. Oct 22, 2026
    1 site added
    Show site
    • Oregon Health and Science University · Portland, United States
    + 1 other change: verification date
  2. Sep 25, 2026
    1 site added
    Show site
    • ChristianaCare Health System · Newark, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07154290
Responsible party
Sponsor
First posted
Sep 4, 2025
Start date
Mar 18, 2026
Primary completion
Jun 10, 2030 (estimated)
Completion
Jun 10, 2030 (estimated)
Last update
Oct 22, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ubamatamab

Start the discussion